Onepot AI

Onepot AI, founded in 2025, is based in South San Francisco, US. The company specializes in AI-driven small molecule synthesis and has completed 2 deals.Onepot specializes in AI-enabled small molecule synthesis, offering a robust platform that encrypts molecular structures end-to-end for secure data handling. The core product leverages advanced algorithms to optimize the design and synthesis of small molecules, which are essential in pharmaceutical research and development. This service is particularly relevant for researchers and companies focused on drug discovery, as it allows for the rapid and secure generation of molecular candidates. Onepot's solutions cater primarily to the pharmaceutical and biotechnology sectors, targeting clients engaged in developing new therapeutics, with a focus on markets in North America, Europe, and Asia.Onepot generates revenue through a subscription-based model that provides access to its synthesis platform. Clients, primarily from the pharmaceutical and biotech industries, engage with the company on an ongoing basis, paying for various tiers of service that may include additional features such as advanced analytics and increased synthesis capacity. The pricing structure accommodates a range of client needs, from small research teams to large pharmaceutical corporations, ensuring flexibility in how clients can access and utilize Onepot’s offerings. Transactions are typically structured as direct business-to-business engagements, where clients may enter into annual contracts or project-based agreements based on their specific molecular synthesis requirements. This strategic investment aims to support upcoming product developments and bolster the company’s capacity in the pharmaceutical market.

1. Seed

   Nov 19, 2025

   Amount

   Undisclosed

   Investors

   Locked